• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21054 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Optical coherence tomography angiography in vascular eye diseases]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Intensity-modulated radiotherapy for prostate cancer]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Coronary intravascular lithotripsy in coronary artery disease]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [OncotypeDX in breast cancer]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Swallowable gastric balloon in obesity]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Electrosurgical units in surgery]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Biofeedback in adults with urinary and/or fecal incontinence]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Stem cell therapy in selected orthopedic conditions]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Transient elastography in non-alcoholic fatty liver disease]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Cryopreservation of eggs and sperm in patients initiating cancer therapy that may affect fertility]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Trastuzumab with pertuzumab in HER2-positive breast cancer]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Embolization or sclerotherapy of pelvic veins in pelvic congestion syndrome]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Platelet-rich plasma in certain orthopedic conditions]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Bariatric surgery in obese patients with gastroesophageal reflux and/or Barrett’s esophagus]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Antiangiogenic drugs in refractory age-related macular degeneration]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Prenatal cell-free DNA in maternal blood screening to assess chromosomal disorders in single pregnancy]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Adjunctive colposcopy technologies (videocolposcopy) for cervical conditions]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Corneal collagen crosslinking with riboflavin in keratoconus]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Fluorodopa PET scanning in Parkinson’s disease]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Radiofrequency-assisted surgery in inferior turbinate hypertrophy]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Onasemnogene abeparvovec (Zolgensma®) for spinal muscular atrophy]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Casirivimab and imdevimab to treat Covid-19 in patients negative for the Omicron genotype]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Fecal microbiota transplantation for recurrent Clostridioides difficile infection]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Sialendoscopy for obstructive salivary gland disease]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [308nm excimer laser or 308nm excimer light in patients with vitiligo]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Vagus nerve stimulation for drug-resistant epilepsy]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Gated-SPECT in ischemic non-obstructive coronary artery disease (microvascular angina - INOCA)]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Elexacaftor/tezacaftor/ivacaftor in cystic fibrosis]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Lutetium 177 PSMA in patients with prostate cancer]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [PSMA PET/CT staging in patients with prostate cancer biochemical recurrence]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Neurophysiological facial nerve monitoring during parotid gland surgery]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Anorectal biofeedback therapy in primary constipation]
2022     Agency for Care Effectiveness (ACE) GLP-1 receptor agonist injections for treating type 2 diabetes mellitus
2022     Agency for Care Effectiveness (ACE) Recombinant blood products for prophylaxis and management of haemophilia A and B
2022     Agency for Care Effectiveness (ACE) Ciclosporin 0.1% eye drops for treating severe vernal keratoconjunctivitis
2022     Agency for Care Effectiveness (ACE) Acarbose for treating type 2 diabetes mellitus
2022     Agency for Care Effectiveness (ACE) Dolutegravir with lamivudine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection
2022     Agency for Care Effectiveness (ACE) Sodium zirconium cyclosilicate for treating hyperkalaemia
2022     Agency for Care Effectiveness (ACE) Ciclosporin 0.1% eye drops for treating severe keratitis in dry eye disease
2022     Agency for Care Effectiveness (ACE) Nicotine replacement therapies to aid smoking cessation
2022     Agency for Care Effectiveness (ACE) Robot-assisted endovascular intervention systems for coronary artery disease and other vascular diseases
2022     Agency for Care Effectiveness (ACE) Magnetic resonance image guided radiation therapy for patients with cancer
2022     Agency for Care Effectiveness (ACE) Cooral System for the prevention of oral mucositis
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Valoctocogene roxaparvovec (haemophilia A) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tonsillectomy or tonsillotomy: evidence report for the S3 guideline on treatment of inflammatory diseases of the palatine tonsils/tonsillitis]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Systematic search for registries in the therapeutic indication of acute lymphoblastic leukaemia]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Systematic search for registries in the therapeutic indication haemophilia B (congenital factor IX deficiency)]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (thyroid cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (advanced NSCLC with RET fusion) - Benefit assessment according to § 35a SGB V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selinexor (multiple myeloma, second line) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selinexor (multiple myeloma, fifth line) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (juvenile psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (enthesitis-associated arthritis) - Benefit assessment according to § 35a SGB V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the final study protocol and statistical analysis plan on routine practice data collection for onasemnogene abeparvovec - Third addendum to Commission A20-61]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for heart transplantation]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pulmonary thrombectomy using a disc retriever for pulmonary artery embolism]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Preoperative risk factors: evidence report for the S3 guideline on treatment of inflammatory diseases of the palatine tonsils/tonsillitis]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab/trastuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (renal cell carcinoma) - Benefit assessment according to § 35a SGB V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (melanoma, advanced) - Benefit assessment according to § 35a SGB V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (melanoma, adjuvant) - Benefit assessment according to § 35a SGB V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (gastric cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (colorectal cancer) - Benefit assessment according to § 35a SGB V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (cervical cancer) - Benefit assessment according to § 35a SGB V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (breast cancer) - Benefit assessment according to § 35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (breast cancer) - Addendum to Commission A22-63]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Palbociclib (breast cancer) - Benefit assessment according to § 35a SGB V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Palbociclib (breast cancer, combination with an aromatase inhibitor) - Addendum to Commission A22-66]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olipudase alfa (ASMD) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (breast cancer, adjuvant) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (oesophageal carcinoma, combination with ipilimumab) - Addendum to Commission A22-55]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nirmatrelvir/ritonavir (COVID-19) - Benefit assessment acc. to § 35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mosunetuzumab (follicular lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Melphalan flufenamide (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Medical eradication: evidence report for the S3 guideline on treatment of inflammatory diseases of the palatine tonsils/tonsillitis]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Inebilizumab (neuromyelitis optica spectrum disorders [NMOSD]) - Benefit assessment according to § 35a SGB V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glycopyrronium (axillary hyperhidrosis) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eravacycline (complicated intra-abdominal infections) - Assessment according to §35a (para. 1c) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eptinezumab (migraine) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial carcinoma) - Addendum to Commission A22-61]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial cancer) - 2nd addendum to commission A22-61]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eladocagene Exuparvovec (aromatic L-amino acid decarboxylase deficiency, = 18 months) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Efgartigimod alfa (myasthenia gravis) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Duration of antibiotic therapy: evidence report for the S3 guideline on treatment of inflammatory diseases of the palatine tonsils/tonsillitis]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Difelikefalin (pruritus) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection for valoctocogene roxaparvovec acc. to the Law for More Safety in the Supply of Medicines (GSAV)]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection for fedratinib acc. to the Law for More Safety in the Supply of Medicines (GSAV)]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cerliponase alfa (neuronal ceroid lipofuscinosis type 2) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V (expiry of the decision)]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceftolozane/tazobactam (bacterial infections < 18 years) - Assessment according to §35a (para. 1c) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Capmatinib (advanced NSCLC with METex14 skipping mutation) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (thyroid cancer) - Addendum to Commission A22-59]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Burosumab (FGF23-related hypophosphataemia) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brexucabtagene autoleucel (acute lymphatic r/r B cell leukemia, from 26 years of age) - Assessment according to §35a SGB V (1), Sentence 11]